title: CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism.
abstract: CD73 is a GPI-anchored lymphocyte adhesion molecule possessing an ecto-5'-nucleotidase enzyme activity. In this work, we show that engagement of lymphocyte CD73 increases lymphocyte binding to cultured endothelial cells (EC) in an LFA-1-dependent fashion. Engagement of CD73 by an anti-CD73 mAb 4G4 increases the adhesion of lymphocytes to cultured EC by about 80% compared with that of lymphocytes treated with a negative control Ab, and the increased adhesion can be blocked by an anti-CD18 mAb. The CD73-regulated increase in lymphocyte adhesion is not due to a conformational change leading to high-affinity LFA-1 receptors as assayed using mAb 24 against an activation-induced epitope of the molecule. Instead, CD73 engagement induces clustering of LFA-1 that is inhibitable by calpeptin, indicating involvement of Ca(2+)-dependent activation of a calpain-like enzyme in this process. In conclusion, the results shown here demonstrate that CD73 regulates the avidity of LFA-1 by clustering. This indicates a previously undescribed role for CD73 in controlling the poorly characterized activation step in the multistep cascade of lymphocyte extravasation. Moreover, these results suggest that in physiological conditions the activation step may result in clustering of LFA-1 rather than in an affinity change of the molecule.
authors.affiliation: MediCity Research Laboratory, Turku University, and National Public Health Institute, Turku, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Airas
authors.forename: J
authors.initials: J
authors.lastname: Niemelä
authors.forename: S
authors.initials: S
authors.lastname: Jalkanen
mesh_terms: D015720:5'-Nucleotidase / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000378:metabolism; D002154:Calpain / Q000037:antagonists & inhibitors; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology*; D002450:Cell Communication / Q000187:drug effects / Q000276:immunology*; D002460:Cell Line; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D016169:Lymphocyte Function-Associated Antigen-1 / Q000378:metabolism / Q000502:physiology*; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D011940:Receptor Aggregation / Q000187:drug effects / Q000276:immunology; D014471:Umbilical Veins; D015854:Up-Regulation / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D016169:Lymphocyte Function-Associated Antigen-1; C071482:calpeptin; D015720:5'-Nucleotidase; D002154:Calpain